

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Murphy, et al.**

Serial No.: **Not Yet Known** **Group: Not Yet Assigned**

Filing Date: **Filed Herewith** **Examiner: Not Yet Assigned**

Title: **METHODS OF MODIFYING EUKARYOTIC CELLS**

July 21, 2003

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

☒ (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart

foreign application not more than three months prior to the date of the filing of this IDS; or

- [] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- [] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- [] (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

- [] (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

- [] (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

- [] This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

REQUEST FOR TRANSFER OF REFERENCE COPIES


- [] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/784,859, U.S. file date 16 February 2001, be transferred to the subject application for consideration by the Examiner. In addition, applicants enclose a copy of WO 94/02602 published February 3, 1994.

Att. Docket No.: REG 780BZ
USSN: Not Yet Known
File Date: Filed Herewith
Murphy, et al.
Information Disclosure Statement

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$_____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted



Linda O. Palladino

Reg. No. 45,636

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. REG 780BZ

Serial No. Not Yet Known

Date Filed Filed Herewith

Applicant: Murphy and Yancopoulos

For METHODS OF MODIFYING EUKARYOTIC CELLS

July 21, 2003

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	<u>5,789,215</u>	<u>8/4/98</u>	<u>Berns, et al.</u>	_____	_____
_____	<u>5,770,429</u>	<u>6/23/98</u>	<u>Lonberg, et al.</u>	_____	_____
_____	<u>5,436,149</u>	<u>7/25/95</u>	<u>Barnes</u>	_____	_____

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	WO94/02602	02/03/1994	PCT		

OTHER DOCUMENTS

Examiner
Initials

_____ NATURE, Vol. 317, 1985, Smithies, O., et al., "Insertion of DNA sequences into the human chromosomal β -globin locus by homologous recombination," pp. 230-234.

- _____ CELL, Vol. 51, 1987, Thomas, K.R., and Capecchi, M.R., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," pp. 503-512.
- _____ NATURE, Vol. 369, 1994, Cheng, S., et al., "Long PCR," pp. 684-685.
- _____ PCR METHODS AND APPLICATIONS, 1994, Foord, O.S., and Rose, E.A., "Long-distance PCR," pp. 3:S149-S161.
- _____ NUCLEIC ACIDS RESEARCH, Vol. 20, 1992, Ponce, M.R., and Micol, J.L., "PCR amplification of long DNA fragments," p.623.
- _____ GENE TARGETING-A PRACTICAL APPROACH, 2nd Ed., 2000, Edited by Joyner, A.L., Hasty, P. et al., Chapter 1 "Gene targeting, principles, and practice in mammalian cells," pp. 1-35.
- _____ MOLECULAR AND CELLULAR BIOLOGY, Vol. 12, 1992, Deng, C., and Capecchi, M.R., "Reexamination of Gene Targeting Frequency as a Function of the Extent of Homology between the Targeting Vector and the Target Locus," pp. 3365-3371.
- _____ NATURE GENETICS, Vol. 20, 1998, Zhang, Y., et al., "A new logic for DNA engineering using recombination in *Escherichia coli*," pp. 123-128.
- _____ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Angrand, P., et al, "Simplified generation of targeting constructs using ET recombination," pp. 16(e).

- ____ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Muyrers, J.P., et al., "Rapid modification of bacterial artificial chromosomes by ET-recombination," pp. 1555-1557.
- ____ Genomics, Vol. 64, 1999, Hill, F., et al., "BAC Trimming: Minimizing Clone Overlaps," pp. 111-113.
- ____ NATURE BIOTECHNOLOGY, Vol. 15, 1997, Yang, X, et al., "Homologous recombination based modification in *Escherichia coli* and germline transmission in transgenic mice of a bacterial artificial chromosome," pp. 859-865.
- ____ PROC. NATL. ACAD. SCI. USA, Vol. 97, 2000, Yu, D., et al., "An efficient recombination system for chromosome engineering in *Escherichia coli*," pp. 5978-5983.
- ____ CURR OPIN BIOTECHNOL, Vol. 9, 1998, Lie, Y.S., and Petropoulos, C.J., "Advances in quantitative PCR technology: 5' nuclease assays," pp. 43-48.
- ____ EUR J CHEM, Vol. 6, 2000, Tan, W., et al., "Molecular Beacons: A Novel DNA Probe for Nucleic Acid and Protein," pp. 1107-1111.
- ____ HUM GENET, Vol. 96, 1995, Laan, M., et al., "Solid-phase minisequencing confirmed by FISH analysis in determination of gene copy number," pp. 275-280.
- ____ TRENDS IN GENETICS, Vol. 13, 1997, Forozan, F., et al., "Genome screening by comparative genomic hybridization," pp. 405-409.

- _____ JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 17G, 1993,
Thompson, C.T., and Gray, J.W., "Cytogenetic Profiling Using
Fluorescence *In Situ* Hybridization (FISH) and Comparative
Genomic Hybridization (CGH)," pp. 139-143.
- _____ AMERICAN JOURNAL OF PATHOLOGY, Vol. 145, 1994,
Houldsworth, J, and Chaganti, R.S.K., "Comparative
Genomic Hybridization: An Overview," p. 1253-1260.
- _____ NATURE GENETICS, Vol. 19, 1998, Lizardi, P.M., et al.,
"Mutation detection and single-molecule counting using
isothermal rolling-circle amplification," pp. 225-232.
- _____ NUCLEIC ACIDS RESEARCH, Vol. 27, 1999, Mitra, R.D., and
Church, G.M., "In situ localized amplification and contact
replication of many individual DNA molecules," pp. e34.
- _____ PROC NATL ACAD SCI USA, Vol. 97, 2000, Tomizuka, K., et
al., "Double trans-chromosomal mice: Maintenance of two
individual human chromosome fragments containing Ig
heavy and κ loci and expression of fully human antibodies,"
pp. 722-727.
- _____ NATURE GENETICS, Vol. 20, 1998, Herault, Y., et al.,
"Engineering chromosomes in mice through targeted meiotic
recombination (TAMERE)," pp. 381-384.


REG 780BZ
USSN Not Yet Known
File Date: Filed Herewith
Murphy, et al.
Information Disclosure Statement

EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: 
Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400